SC
ALNY icon

Schubert & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Schubert & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-5
Closed -$1K – 95
2023
Q1 		$1K Sell
5
-3
-38% -$631 ﹤0.01% 1194
2022
Q4 		$1.9K Buy
8
+3
+60% +$640 ﹤0.01% 906
2022
Q3 		$1K Hold
5
– – ﹤0.01% 985
2022
Q2 		$1K Buy
5
+1
+25% +$142 ﹤0.01% 968
2022
Q1 		$1K Sell
4
-1
-20% -$152 ﹤0.01% 550
2021
Q4 		$1K Buy
+5
New +$929 ﹤0.01% 503

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Schubert & Co's ALNY Position: Q2 2023 in Review

Schubert & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2023, closing a stake of 5 shares — an estimated $1K sold.

Schubert & Co first reported a position in ALNY in Q4 2021 and held it in 6 quarters. The position peaked at $1.9K in Q4 2022. 476 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

  • Schubert & Co reported no remaining Alnylam Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 5 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $1K.
  • Schubert & Co first reported a position in Alnylam Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Alnylam Pharmaceuticals position peaked at $1.9K in Q4 2022.
  • 476 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.